Scholarlink

Background and aim <p>Hepatocellular carcinoma (HCC) is the predominant primary liver cancer and third leading cause of cancer-related death. Despite improvements in overall survival (OS), those in HCC-specific survival rates remain modest. Tyrosine kinase inhibitors (TKIs) are crucial first-line HCC treatments when immune checkpoint inhibitors are unsuitable. To identify plasma biomarkers predicting the therapeutic response to TKIs in patients with HCC.</p> Methods <p>Pre-treatment plasma samples from 60 patients with advanced HCC treated with sorafenib or lenvatinib were analyzed using targeted proteomics. Differentially expressed proteins were identified based on the treatment response (<i>P</i> &lt; 0.05).</p> Results <p>Plasma levels of metalloproteinase 12 and vascular endothelial growth factor A were elevated in patients with progressive disease compared with those with partial response or stable disease, correlating with shorter progression-free survival (PFS) and OS. Among patients with PFS ≥ 12 months, C-C motif chemokine ligand 20, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 5, fibroblast growth factor 2, interleukin (IL)-7, IL-8, IL-18, latency-associated peptide transforming growth factor beta 1, and mucin 16 expressions were significantly upregulated, with IL-8 (CXCL8) levels demonstrating the highest predictive accuracy (area under the receiver operating characteristic = 0.91) and prognostic power for PFS (hazard ratio; HR = 2.97, <i>P</i> = 0.0015) and OS (HR = 3.64, <i>P</i> = 0.001). <i>CXCL8</i> expression was predominantly localized in tumor-associated myeloid cells and enriched in epithelial–mesenchymal transition- and immune modulation-related pathways, highlighting its importance in the tumor microenvironment.</p> Conclusions <p>Elevated plasma IL-8 levels are strongly associated with poor outcomes in patients with advanced HCC undergoing TKI treatment, suggesting a potential role for IL-8 in guiding TKI therapeutic decisions and identifying high-risk patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma interleukin-8 as a predictive biomarker for tyrosine kinase inhibitor response in advanced hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Sujin Kim,
  • Hye Ri Ahn,
  • Hui Gyeong Kim,
  • Dooyeon Kim,
  • Ji Eun Han,
  • Soon Sun Kim,
  • Jae Youn Cheong,
  • Jung Woo Eun,
  • Hyo Jung Cho

摘要

Background and aim

Hepatocellular carcinoma (HCC) is the predominant primary liver cancer and third leading cause of cancer-related death. Despite improvements in overall survival (OS), those in HCC-specific survival rates remain modest. Tyrosine kinase inhibitors (TKIs) are crucial first-line HCC treatments when immune checkpoint inhibitors are unsuitable. To identify plasma biomarkers predicting the therapeutic response to TKIs in patients with HCC.

Methods

Pre-treatment plasma samples from 60 patients with advanced HCC treated with sorafenib or lenvatinib were analyzed using targeted proteomics. Differentially expressed proteins were identified based on the treatment response (P < 0.05).

Results

Plasma levels of metalloproteinase 12 and vascular endothelial growth factor A were elevated in patients with progressive disease compared with those with partial response or stable disease, correlating with shorter progression-free survival (PFS) and OS. Among patients with PFS ≥ 12 months, C-C motif chemokine ligand 20, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 5, fibroblast growth factor 2, interleukin (IL)-7, IL-8, IL-18, latency-associated peptide transforming growth factor beta 1, and mucin 16 expressions were significantly upregulated, with IL-8 (CXCL8) levels demonstrating the highest predictive accuracy (area under the receiver operating characteristic = 0.91) and prognostic power for PFS (hazard ratio; HR = 2.97, P = 0.0015) and OS (HR = 3.64, P = 0.001). CXCL8 expression was predominantly localized in tumor-associated myeloid cells and enriched in epithelial–mesenchymal transition- and immune modulation-related pathways, highlighting its importance in the tumor microenvironment.

Conclusions

Elevated plasma IL-8 levels are strongly associated with poor outcomes in patients with advanced HCC undergoing TKI treatment, suggesting a potential role for IL-8 in guiding TKI therapeutic decisions and identifying high-risk patients.